Ongoing case

Brain+ A/S

Back to all cases

Brain+ A/S

16 Sep - 27 Sep 2024Warrant exercise TO 4

About the company

Brain+ is active in the pharmaceutical industry. The company specializes in research and development for the treatment of dementia and Alzheimer’s. The product portfolio includes, for example, cognitive stimulation therapy. In addition to the main business, service and associated ancillary services are also offered. The business is run with largest presence in Europe. Brain+ has its headquarters in Copenhagen.

Read more on the company's website

The offer in summary

Subscription period: 16 September - 27 September 2024

Price per share : DKK 0.08

Trading with warrants: Until September 25, 2024

The offer: 65 496 978 new shares

Terms: One (1) warrant of series TO 4 gives the holder the right to subscribe for one (1) new share.

Marketplace: Nasdaq First North Copenhagen

Financial adviser: Sedermera Corporate Finance

Documents

  Tegningsformular TO 4

Disclaimer

Due to restrictions in applicable law in the United States, Canada, Australia, Hong Kong, Singapore, South Africa, Switzerland, New Zealand, Japan, Russia, Belarus or other countries where participation requires further prospectuses, registrations or actions other than those under Swedish law, the offer to subscribe for securities in this offer is not directed at persons or others with registered address in any of these countries.